
HeartFlow Inc (HTFL) Stock Forecast & Price Target
HeartFlow Inc (HTFL) Analyst Ratings
Bulls say
HeartFlow Inc. experienced robust revenue growth, with 3Q25 revenues reaching $46.3 million, a year-over-year increase of approximately 41%, which surpassed projections due to strong uptake of its FFR-CT coronary disease analysis software. The company's gross margins improved significantly to 76.8%, reflecting a 90 basis points increase year-over-year, highlighting the financial health and efficiency of its operations. Additionally, management indicated a positive outlook for future growth, bolstered by increasing adoption of coronary CT angiography, new account acquisition, and plans to incorporate plaque analysis revenues by 2026, which further supports a favorable long-term forecast for the company.
Bears say
HeartFlow Inc. has consistently incurred significant net losses, totaling $95.7 million and $96.4 million for FY23 and FY24, respectively, with expectations for further substantial losses in the foreseeable future, raising concerns about the company's ability to achieve profitability. The company's revenue guidance for 2025 reflects limited growth, forecasting approximately $173 million which suggests stagnant performance, especially given the anticipated flat revenue for Q4 2025 compared to Q3 2025. Additionally, the reliance on adherence to specific clinical guidelines by healthcare providers and potential reimbursement challenges pose substantial risks to the adoption and financial viability of HeartFlow's technology, which could adversely impact the company’s business and future prospects.
This aggregate rating is based on analysts' research of HeartFlow Inc and is not a guaranteed prediction by Public.com or investment advice.
HeartFlow Inc (HTFL) Analyst Forecast & Price Prediction
Start investing in HeartFlow Inc (HTFL)
Order type
Buy in
Order amount
Est. shares
0 shares